Neomycin was demonstrated to inhibit the binding of thrombin to intact human platelets. The effects of neomycin on both thrombin binding and thrombin-induced changes in inositol phospholipid metabolism could be reproduced by the thrombin antagonist hirudin. We propose that neomycin inhibits thrombin-induced platelet activation by interference with the cellular receptor.
INTRODUCTION
Receptor-mediated increase in inositol phospholipid metabolism represents one of the major trans-membrane signaltransducing mechanisms (reviewed in [1] ). Upon cellular activation, phosphatidylinositol 4,5-bisphosphate (PIP2) is hydrolysed to inositol 1,4,5-trisphosphate and diacylglycerol, which both act as intracellular messenger molecules [2, 3] . The polycationic antibiotic neomycin binds strongly and relatively specifically to PIP2 [4] [5] [6] . On the basis of this property, neomycin has frequently been used to perturb the turnover of the inositol phospholipids in cells [7] [8] [9] [10] . However, experiments on permeabilized cells have revealed that very different concentrations of neomycin are required to affect the inositol phospholipid turnover in the various cell types. In platelets only 10IUM was required [11] , whereas in mast cells [12] and sea-urchin eggs [13] 1 mm was necessary to inhibit the agonist-induced breakdown of PIP2. Moreover, the data obtained by the use of neomycin have been difficult to interpret, since polyanionic molecules to which it binds also include inositol 1,4,5-trisphosphate and ATP [14] , and at high concentrations the drug has even been shown to induce Ca2+ release and stimulate GTPases [15] . The specificity and the mechanism of the inhibitory effects of neomycin have therefore frequently been debated (reviewed in [16] ).
We have recently suggested that neomycin may interfere with thrombin-induced platelet activation at a level before the inositol phospholipid metabolism [17, 18] (0.1 mCi/ml) for 1 h at 37°C before gel-filtration through Sepharose 2B into a nominally Ca2+-and phosphate-free Tyrode's buffer [20] . The final platelet number was standardized at 3.5 x 108/ml and the cells were incubated at 37 'C. Neomycin was added 90 s before the cells were exposed to thrombin, and after another 90 s 0.5 ml of the platelet suspension was withdrawn and mixed with 2 ml of chloroform/methanol/conc. HCI (20:40:1, by vol.; 0°C). In another method ( Fig. 2) , unlabelled gel-filtered platelets were exposed to neomycin 90 s before addition of 125I-labelled purified thrombin. After 60 s, the cells were mixed with 1 Mformaldehyde/50 mM-EDTA (0 'C) and immediately thereafter centrifuged through silicone oil as described by Holmsen et al. [21] . The radioactivity in the pellet was subsequently determined in a y-radiation spectrometer.
Phospholipid extraction and chromatography
The lipids were extracted from chloroform/methanol/HCl by addition of 0.5 ml of water and 0.5 ml of chloroform [20] . Phospholipids were separated by t.l.c. in chloroform/ methanol/20 % (v/v) methylamine (30:18:5, by vol.) [20] and detected by overnight radioautography. The spots were subsequently scraped off the plates for determination of radioactivity by liquid-scintillation counting.
RESULTS AND DISCUSSION
We have previously suggested that the inhibitory effects of neomycin on thrombin-induced platelet activation may be unrelated to the ability of the drug to bind to phospholipids involved in the signal-transduction process [17, 18] . The inositol phospholipids are generally believed to be located mainly to the inner leaflet of the plasma membrane [22] , and it is still unclear whether the highly polar neomycin molecule can penetrate the intact cellular plasma membrane to interact with the phospholipids on the cytosolic side.
In [32P] PA radioactivity (% of control) in thrombin binding in cells exposed to neomycin or hirudin (Fig.  2) . To ensure that the inhibitory action of the drug was unrelated to an interaction between thrombin and neomycin, we tested whether neomycin affected the ability of thrombin to transfer fibrinogen to fibrin, thereby clotting platelet-poor plasma. In contrast with hirudin, no such effect was found with 8 mmneomycin (results not shown).
Our data clearly demonstrate that neomycin decreases the thrombin binding in intact human platelets. The concentration of neomycin needed to inhibit binding was similar to that required for inhibition of platelet functions [10, 17] . Both the decrease in binding and the thrombin-induced changes in inositol phospholipid metabolism can be reproduced by addition of the thrombin antagonist hirudin. The inhibitory action of neomycin on receptor-mediated cellular activation is therefore not related to the ability of the drug to bind to the phospholipase Chydrolysable inositol phospholipids, as claimed by most authors [7] [8] [9] [10] [11] [12] [13] [14] [15] . Neomycin has previously been shown to inhibit not only thrombin-induced platelet activation but also collagen-and platelet-activating-factor-induced aggregation and secretion [10] . These agonists are all believed to activate the platelet through the inositol phospholipid system, but there is little knowledge about the structure of the cellular receptors. In BHK cells, neomycin inhibited the internalization of Herpes Simplex Virus 1 [24] . This process has been proposed to be dependent on the inositol phospholipid metabolism [25] . However, those authors have shown that neomycin probably inhibits virus internalization by interfering with the cellular receptor function [26, 27] . Inositol phospholipids have been demonstrated as structural elements of some cellular receptors [28] . Although never demonstrated, the thrombin receptor may contain these lipids as well as other negatively charged molecules which may interact with neomycin at millimolar concentrations. We therefore propose that neomycin inhibits the signal-transduction process by interfering with the cellular receptor function.
